Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • OncoSignature high throughput screening platform for the prediction of anticancer drug sensitivity
cell panel screening services
Scientific Poster

OncoSignature high throughput screening platform for the prediction of anticancer drug sensitivity

Learn about how the OncoSignature™ high throughput screening platform can be used for the prediction of anticancer drug sensitivity in this scientific poster. Our preclinical services team demonstrate the platform's applicability to drug sensitivity applications through a case study identifying predictors of sensitivity to BRAF inhibitors.

The poster has been converted into a digital-friendly layout for ease of reading.

Download to learn more and explore the data.


For research use only. Not for use in diagnostic procedures.
 

Download Resource

OncoSignature high throughput screening platform for the prediction of anticancer drug sensitivity

Download Scientific Poster
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.